Objective. Based on the immunosuppressive effects of blood transfusions in organ transplantation, we determined the effect of a blood transfusion on disease activity of rheumatoid arthritis (RA).
Rheumatoid arthritis (RA) is an autoimmune disease transfusions was also observed in RA. In addition, several uncontrolled studies reported a beneficial effect frequently treated with immunosuppressive drugs. Blood transfusions were reported to have immunosuppressive of blood transfusions on arthritis activity in RA [6] [7] [8] [9] . The present double-blind, placebo-controlled, pilot effects and might thus be beneficial to RA patients.
Blood transfusion, when given to the recipients prior study aims to investigate whether one blood transfusion matched for one HLA-A, -B and -DR antigen, and to renal transplantation, was found to prolong allograft survival [1] . If the blood was matched for one HLA-DR mismatched for the other HLA-A, -B and -DR antigen, given as an adjuvant therapy, diminishes disease activity antigen between blood donor and acceptor, the chance of rejection of the graft [2] was even further reduced.
of RA. In addition, in some cases of recurring spontaneous abortions, a beneficial effect of blood transfusions was a placebo infusion. The patient, as well as the trained Outcome parameters observer who studied the patient after the transfusion,
The disease activity of RA was measured by outcome were blinded for the intervention by covering both the parameters as defined in the ACR 20% criteria [11] . units of fluid and i.v. lines during the procedure as well
Immunological monitoring as the results of the blood tests.
Clinical and demographic data were documented at HLA alloantibodies were measured in each patient study entry. before and after the (blood ) transfusion. This was tested All patients were typed for ABO, rhesus, Kell, Duffy by an ELISA technique which could detect HLA class and Kidd blood groups, for HLA class I (A, B and C ), I IgA, M and G antibodies. Positive sera were screened DR and DQ by serological methods, and for class II by against a selected panel of lymphocytes to determine the polymerase chain reaction (PCR)-SSO and PCR-SSP;
HLA antibody specificities. DRB1 PCR-SSP subtyping was performed in the case Statistics of DR4 and DR6. Moreover, serum was screened for irregular antibodies, and for HLA-A, -B and -C The patients treated with placebo or blood transfusion antibodies.
were tested whether or not they met the ACR 20% All 40 patients were assessed by a trained observer at response criteria. Apart from the combination of parastudy entry (visit 1), and 2 weeks (visit 2), 1 month meters in the ACR response criteria, every parameter (visit 3), 3 months (visit 4) and 6 months (visit 5) after was considered separately as well. the transfusion. The patients were monitored for the The follow-up of patients was according to the intenmedication used and additional medical treatment. At tion-to-treat analysis. every visit, the 28 joint count for swelling and pain A x2 test was performed in the case of dichotomous (including the Ritchie score), ESR and a full blood data. In the case of non-normally distributed data, the count were obtained. Also, a Health Assessment Kruskal-Wallis and Median tests were used. The change Questionnaire (HAQ) and visual analogue scales ( VAS ) between the first visit and each follow-up assessment of of morning stiffness, disease activity and pain were the distinct variables was compared between both arms completed at every visit by the patient as well as a in a one-way ANOVA. In order to rule out the effect of global assessment of the disease activity by the the rise in haemoglobin as the cause of improvement, a investigator.
covariance analysis of each parameter was performed in The medication, including anti-rheumatic drugs, had addition. to be stable 3 months prior to study entry and was continued at the same dosage during 6 months after the
Results transfusion. A change of anti-rheumatic drugs or interventions considered necessary because of sustained RA
Outcome of RA disease activity during the 6 months of follow-up was No significant difference between the placebo group and considered as a failure of the therapy. the blood transfusion group was observed according to The study was approved by the medical ethical comsex, age, disease duration and number of patients with mittee of the hospital.
erosive disease ( Table 1) . The number of patients with increased serum rheumatoid factor levels and nodular Blood transfusion: product specification and HLA disease was higher in the blood transfusion group, but matching Thirty patients received one unit (250 cm3) of erythro- Ten patients received a placebo infusion of 250 cm3
No DMARD 2 (7) 1 (10) 0.9% natrium chloride.
this difference was not significant. The use of diseasepercentage of patients responding to the ACR criteria between the groups treated with placebo or blood transmodifying anti-rheumatic drugs (DMARDs) in both groups was similar, as well as the percentage of patients fusion were not significant. Logistic regression of the patients fulfilling these criteria during the course of the without DMARDs ( Table 1) . Also, the baseline characteristics of disease activity and haemoglobin level were observation period did not show a significant difference between the placebo and blood transfusion group equal in both groups at entry to the study ( Table 2) .
Two patients in the placebo group were considered (P = 0.28). None of the individual patients met the response as failures: one because a DMARD was started 2 weeks after the infusion and one because of a hospital admiscriteria at more than two visits. Only one out of the four patients (including one from the placebo group) sion for orthopaedic surgery 3 months after the infusion. Eight patients receiving the blood transfusion had a who showed a response at more than one visit responded within 1 month after transfusion. Nine patients (includtreatment failure. All received new DMARD therapy within 6 months after the transfusion: two started after ing two from the placebo group) showed a response at only one visit. 2 weeks, one after 3 months, and five between 3 and 6 months after the transfusion.
The individual disease activity parameters showed a larger decrease in the blood transfusion group compared In the blood transfusion group, one (3%) patient responded to the ACR 20% criteria after 2 weeks, two to the placebo group for ESR, HAQ, disease activity according to the patient and the Ritchie score (Fig. 2) . (6%) patients after 1 month, five (20%) after 3 months and five (20%) after 6 months (Fig. 1) . In the placebo
In contrast, the global disease activity score according to the doctor decreased more in the placebo-treated group, no patients responded after 2 weeks and 1 month, one (10%) after 3 months and three (30%) after patients. After correction for the increase in haemoglobin levels, the statistical significance of the decrease 6 months of follow-up (Fig. 1 ). The differences in the in ESR in the blood transfusion group disappeared T 2. Median value (and range) of the baseline characteristics of (P = 0.84; Table 3 ). The beneficial effect of the blood also remained significant ( Table 3) . No donor-specific HLA class I antibodies were detected Swollen joint count 13 (6-26) 15 (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) in the placebo group. Seven patients (23%) showed donor-specific antibodies after blood transfusion ( Table 4) . In three cases, the donor-specific antibodies were associated with an improvement of RA according to the ACR criteria.
Discussion
This is the first placebo-controlled and double-blind study on the effect of a blood transfusion on disease activity in RA. Given the experiences in organ transplantation, blood was used with one HLA-A, -B and -DR antigen match (with a mismatch for the other HLA-A, -B and -DR antigen) between donor and recipient. Within 1 month after the blood transfusion, two patients fulfilled the ACR response criteria, with none in the placebo group. After 3 and 6 months, the percentage of patients who fulfilled the ACR 20% response criteria in the groups who received a blood transfusion and the placebo did not differ significantly. Several individual disease activity parameters, including the ESR, HAQ, Ritchie score and pain score according to change in haemoglobin levels, the significance of the T 3. Mean differences (delta) of the change in the outcome ESR change disappeared and stronger improvement of parameters of the placebo group minus the blood transfusion group after adjustment for the haemoglobin correction the HAQ and Ritchie score in the blood transfusion group remained significant. These findings justify the Parameter Delta (..) P conclusion that a blood transfusion had a mild antiinflammatory effect on RA. The study was not designed illustrated by a higher percentage of renal allograft survival after a HLA-A and -B compatible blood trans- The mechanism by which the blood transfusion UK, however, these kinds of studies cannot be performed because the white blood cells have to be removed matched for one DR antigen has a long-lasting beneficial effect on renal graft survival remains unclear. It can be from the transfused blood because of the theoretical risk of Creutzfeld-Jacob disease. Nevertheless, we conhypothesized that host T cells, which recognize 'autologous' class II antigens on leucocytes of the blood donor, clude that the results of the present study support further attempts to develop anti-rheumatic therapies by means are downregulated, either by the induction of T-suppressor cells or by the deletion of cytotoxic T cells of immune deviation through the administration of partly matched allogenic HLA antigens. directed against these 'autologous' antigens [2, [14] [15] [16] .
The observation that RA improves after a blood transfusion was first described in 1931 by Copeman [17] . A 'dramatic' improvement of pain and swollen
